| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 34 | 2025 | 1230 | 4.270 |
Why?
|
| Mammary Glands, Animal | 19 | 2023 | 79 | 3.340 |
Why?
|
| Tumor Suppressor Protein p53 | 24 | 2023 | 314 | 3.300 |
Why?
|
| Penaeidae | 8 | 2024 | 10 | 2.810 |
Why?
|
| Estrogens | 9 | 2022 | 117 | 2.250 |
Why?
|
| Mammary Neoplasms, Animal | 8 | 2022 | 29 | 2.140 |
Why?
|
| Mammary Glands, Human | 8 | 2019 | 56 | 2.050 |
Why?
|
| Li-Fraumeni Syndrome | 5 | 2023 | 7 | 1.810 |
Why?
|
| Mammary Neoplasms, Experimental | 8 | 2022 | 63 | 1.810 |
Why?
|
| Transcriptome | 6 | 2020 | 409 | 1.650 |
Why?
|
| Genes, p53 | 9 | 2023 | 51 | 1.580 |
Why?
|
| Gene Expression Regulation, Neoplastic | 9 | 2020 | 593 | 1.310 |
Why?
|
| Receptors, Estrogen | 8 | 2023 | 130 | 1.140 |
Why?
|
| Mice, Inbred BALB C | 21 | 2021 | 894 | 1.100 |
Why?
|
| Perciformes | 3 | 2026 | 4 | 1.100 |
Why?
|
| Animals | 64 | 2026 | 21529 | 1.080 |
Why?
|
| Progesterone | 6 | 2008 | 168 | 1.040 |
Why?
|
| Polymorphism, Single Nucleotide | 6 | 2021 | 511 | 0.900 |
Why?
|
| Mice | 39 | 2025 | 11215 | 0.890 |
Why?
|
| Quantitative Trait Loci | 5 | 2022 | 79 | 0.880 |
Why?
|
| Environmental Exposure | 4 | 2020 | 222 | 0.880 |
Why?
|
| Benzophenones | 3 | 2020 | 20 | 0.820 |
Why?
|
| Parabens | 2 | 2021 | 6 | 0.810 |
Why?
|
| Gene Expression Profiling | 9 | 2020 | 800 | 0.810 |
Why?
|
| Apoptosis | 7 | 2020 | 1108 | 0.780 |
Why?
|
| Densovirinae | 1 | 2022 | 1 | 0.740 |
Why?
|
| Allergens | 4 | 2026 | 57 | 0.710 |
Why?
|
| Genes, Modifier | 1 | 2021 | 4 | 0.700 |
Why?
|
| Female | 55 | 2025 | 34125 | 0.690 |
Why?
|
| Laboratory Personnel | 1 | 2020 | 2 | 0.670 |
Why?
|
| Laboratories | 1 | 2020 | 27 | 0.660 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2021 | 90 | 0.660 |
Why?
|
| Gills | 1 | 2020 | 7 | 0.650 |
Why?
|
| Genetic Predisposition to Disease | 8 | 2023 | 743 | 0.650 |
Why?
|
| DNA Repair | 2 | 2021 | 261 | 0.650 |
Why?
|
| Gene Expression Regulation | 5 | 2021 | 1635 | 0.650 |
Why?
|
| Chromosome Mapping | 5 | 2021 | 297 | 0.640 |
Why?
|
| Stem Cells | 2 | 2013 | 273 | 0.620 |
Why?
|
| Adaptation, Physiological | 1 | 2020 | 131 | 0.610 |
Why?
|
| Biomarkers, Tumor | 2 | 2020 | 525 | 0.610 |
Why?
|
| Epithelial Cells | 10 | 2022 | 418 | 0.600 |
Why?
|
| DNA Replication | 1 | 2021 | 249 | 0.600 |
Why?
|
| Environmental Pollutants | 1 | 2020 | 97 | 0.570 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2019 | 157 | 0.560 |
Why?
|
| Kidney | 2 | 2020 | 456 | 0.560 |
Why?
|
| Mice, Knockout | 10 | 2021 | 2162 | 0.540 |
Why?
|
| Genome | 3 | 2020 | 287 | 0.530 |
Why?
|
| Fish Proteins | 3 | 2026 | 10 | 0.510 |
Why?
|
| Food Hypersensitivity | 3 | 2026 | 26 | 0.500 |
Why?
|
| Introduced Species | 1 | 2016 | 2 | 0.490 |
Why?
|
| Tilapia | 1 | 2016 | 2 | 0.490 |
Why?
|
| Biota | 1 | 2016 | 3 | 0.490 |
Why?
|
| Fresh Water | 1 | 2016 | 13 | 0.480 |
Why?
|
| Parity | 2 | 2014 | 71 | 0.480 |
Why?
|
| Genetics, Population | 1 | 2016 | 47 | 0.470 |
Why?
|
| Disease Models, Animal | 9 | 2021 | 2283 | 0.460 |
Why?
|
| Epithelium | 5 | 2010 | 100 | 0.430 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2018 | 663 | 0.430 |
Why?
|
| Mucins | 2 | 2020 | 27 | 0.420 |
Why?
|
| Immunoconjugates | 2 | 2025 | 96 | 0.410 |
Why?
|
| Membrane Proteins | 1 | 2019 | 928 | 0.400 |
Why?
|
| Receptors, Notch | 2 | 2011 | 110 | 0.400 |
Why?
|
| Humans | 42 | 2026 | 65528 | 0.390 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2013 | 33 | 0.390 |
Why?
|
| Estradiol | 2 | 2018 | 261 | 0.380 |
Why?
|
| Breast | 4 | 2020 | 193 | 0.370 |
Why?
|
| Cell Lineage | 1 | 2013 | 283 | 0.350 |
Why?
|
| DNA | 1 | 2016 | 855 | 0.340 |
Why?
|
| Activins | 1 | 2011 | 55 | 0.340 |
Why?
|
| Australia | 3 | 2022 | 129 | 0.340 |
Why?
|
| Genetic Linkage | 3 | 2021 | 98 | 0.330 |
Why?
|
| Lactation | 5 | 2023 | 77 | 0.330 |
Why?
|
| Tissue Transplantation | 1 | 2010 | 9 | 0.330 |
Why?
|
| Cell Line, Tumor | 8 | 2025 | 1611 | 0.320 |
Why?
|
| Transforming Growth Factor beta | 3 | 2011 | 181 | 0.310 |
Why?
|
| Precancerous Conditions | 1 | 2010 | 75 | 0.300 |
Why?
|
| Loss of Heterozygosity | 2 | 2010 | 26 | 0.290 |
Why?
|
| Signal Transduction | 5 | 2019 | 3157 | 0.290 |
Why?
|
| Prenatal Exposure Delayed Effects | 2 | 2021 | 160 | 0.290 |
Why?
|
| Seafood | 2 | 2026 | 14 | 0.280 |
Why?
|
| Fibroblasts | 3 | 2026 | 420 | 0.280 |
Why?
|
| Disease Susceptibility | 4 | 2021 | 167 | 0.280 |
Why?
|
| Heterozygote | 3 | 2007 | 175 | 0.270 |
Why?
|
| Neoplastic Stem Cells | 1 | 2008 | 200 | 0.250 |
Why?
|
| Biosensing Techniques | 3 | 2017 | 124 | 0.250 |
Why?
|
| Tropomyosin | 2 | 2024 | 37 | 0.250 |
Why?
|
| Pregnancy | 9 | 2023 | 2432 | 0.250 |
Why?
|
| Recombination, Genetic | 3 | 2017 | 255 | 0.250 |
Why?
|
| Cytogenetic Analysis | 1 | 2026 | 26 | 0.240 |
Why?
|
| Maytansine | 1 | 2025 | 6 | 0.240 |
Why?
|
| Cell Transformation, Neoplastic | 3 | 2015 | 214 | 0.240 |
Why?
|
| Neoplasms | 5 | 2023 | 1415 | 0.240 |
Why?
|
| Bass | 2 | 2016 | 2 | 0.230 |
Why?
|
| Cyclins | 3 | 2002 | 42 | 0.230 |
Why?
|
| DNA Damage | 5 | 2008 | 300 | 0.220 |
Why?
|
| Cell Culture Techniques | 1 | 2026 | 194 | 0.220 |
Why?
|
| Food Safety | 1 | 2024 | 10 | 0.210 |
Why?
|
| Transcription, Genetic | 1 | 2008 | 923 | 0.210 |
Why?
|
| Genes, p16 | 1 | 2003 | 6 | 0.200 |
Why?
|
| Semen Preservation | 1 | 2023 | 6 | 0.200 |
Why?
|
| Sexual Maturation | 1 | 2023 | 52 | 0.200 |
Why?
|
| Phthalic Acids | 1 | 2023 | 41 | 0.200 |
Why?
|
| Germ-Line Mutation | 1 | 2023 | 49 | 0.190 |
Why?
|
| Mitosis | 1 | 2004 | 223 | 0.190 |
Why?
|
| Polymerase Chain Reaction | 2 | 2022 | 524 | 0.190 |
Why?
|
| Cell Proliferation | 3 | 2026 | 1050 | 0.190 |
Why?
|
| Receptors, Aryl Hydrocarbon | 1 | 2022 | 16 | 0.190 |
Why?
|
| Adolescent | 5 | 2020 | 6383 | 0.190 |
Why?
|
| Risk Factors | 7 | 2019 | 5442 | 0.190 |
Why?
|
| Polychlorinated Biphenyls | 1 | 2022 | 39 | 0.180 |
Why?
|
| Tumor Cells, Cultured | 2 | 2020 | 466 | 0.180 |
Why?
|
| Hormones | 1 | 2002 | 62 | 0.180 |
Why?
|
| DNA-Binding Proteins | 3 | 2010 | 1217 | 0.180 |
Why?
|
| Mice, Transgenic | 2 | 2002 | 1310 | 0.180 |
Why?
|
| Alleles | 1 | 2003 | 457 | 0.180 |
Why?
|
| Antineoplastic Agents | 2 | 2023 | 682 | 0.170 |
Why?
|
| Recombinational DNA Repair | 1 | 2021 | 29 | 0.170 |
Why?
|
| Arthropod Proteins | 1 | 2020 | 8 | 0.170 |
Why?
|
| Genome, Viral | 1 | 2022 | 142 | 0.170 |
Why?
|
| Genetic Loci | 1 | 2021 | 119 | 0.170 |
Why?
|
| Nanostructures | 1 | 2023 | 184 | 0.170 |
Why?
|
| Cells, Cultured | 6 | 2026 | 2211 | 0.170 |
Why?
|
| Salinity | 1 | 2020 | 5 | 0.160 |
Why?
|
| Osmoregulation | 1 | 2020 | 2 | 0.160 |
Why?
|
| Placental Hormones | 1 | 2000 | 1 | 0.160 |
Why?
|
| Excitation Contraction Coupling | 1 | 2020 | 4 | 0.160 |
Why?
|
| Sarcoplasmic Reticulum Calcium-Transporting ATPases | 1 | 2020 | 14 | 0.160 |
Why?
|
| Gene-Environment Interaction | 1 | 2020 | 51 | 0.160 |
Why?
|
| Macrophage Activation | 1 | 2020 | 119 | 0.160 |
Why?
|
| Toxicity Tests | 1 | 2020 | 19 | 0.160 |
Why?
|
| Gene Regulatory Networks | 2 | 2019 | 164 | 0.160 |
Why?
|
| Sunscreening Agents | 1 | 2019 | 23 | 0.150 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 4 | 2017 | 61 | 0.150 |
Why?
|
| Homeostasis | 1 | 2002 | 376 | 0.150 |
Why?
|
| Prognosis | 3 | 2020 | 1792 | 0.150 |
Why?
|
| Hyperplasia | 1 | 2019 | 90 | 0.150 |
Why?
|
| Aquaculture | 1 | 2018 | 1 | 0.150 |
Why?
|
| Cytoplasm | 1 | 2000 | 284 | 0.140 |
Why?
|
| Mammaplasty | 3 | 2014 | 47 | 0.140 |
Why?
|
| Nuclear Proteins | 2 | 2003 | 794 | 0.140 |
Why?
|
| Multigene Family | 1 | 2018 | 106 | 0.140 |
Why?
|
| Adult | 8 | 2020 | 17418 | 0.140 |
Why?
|
| Mitochondria | 2 | 2012 | 404 | 0.140 |
Why?
|
| Genomics | 2 | 2020 | 394 | 0.140 |
Why?
|
| Polymers | 3 | 2010 | 331 | 0.140 |
Why?
|
| Linkage Disequilibrium | 1 | 2017 | 48 | 0.130 |
Why?
|
| Bridged-Ring Compounds | 1 | 2017 | 9 | 0.130 |
Why?
|
| Rats | 4 | 2022 | 2015 | 0.130 |
Why?
|
| Selection, Genetic | 2 | 2017 | 92 | 0.130 |
Why?
|
| Diabetic Angiopathies | 1 | 2017 | 25 | 0.130 |
Why?
|
| Neoplasm Proteins | 1 | 1999 | 289 | 0.130 |
Why?
|
| Endothelial Progenitor Cells | 1 | 2017 | 10 | 0.130 |
Why?
|
| Proto-Oncogene Proteins | 1 | 1999 | 339 | 0.130 |
Why?
|
| Middle Aged | 7 | 2020 | 18266 | 0.130 |
Why?
|
| Mice, Inbred C57BL | 5 | 2017 | 3482 | 0.130 |
Why?
|
| Luminescent Proteins | 1 | 2017 | 132 | 0.130 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2017 | 45 | 0.130 |
Why?
|
| Imidazoles | 1 | 2017 | 86 | 0.130 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2017 | 85 | 0.130 |
Why?
|
| Adenocarcinoma | 1 | 2000 | 361 | 0.130 |
Why?
|
| Cell Nucleus | 3 | 2014 | 639 | 0.130 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2008 | 302 | 0.120 |
Why?
|
| Disease Progression | 2 | 2019 | 1216 | 0.120 |
Why?
|
| Tropical Climate | 1 | 2016 | 3 | 0.120 |
Why?
|
| Population Density | 1 | 2016 | 14 | 0.120 |
Why?
|
| RNA, Long Noncoding | 1 | 2018 | 172 | 0.120 |
Why?
|
| Nanotechnology | 1 | 2017 | 135 | 0.120 |
Why?
|
| Young Adult | 4 | 2020 | 4836 | 0.120 |
Why?
|
| Neoplasm Transplantation | 2 | 2010 | 172 | 0.120 |
Why?
|
| Genetic Variation | 1 | 2018 | 401 | 0.120 |
Why?
|
| Molecular Biology | 1 | 2016 | 67 | 0.110 |
Why?
|
| Estrogen Receptor beta | 1 | 2015 | 24 | 0.110 |
Why?
|
| Mice, Mutant Strains | 2 | 2008 | 303 | 0.110 |
Why?
|
| Ischemia | 1 | 2017 | 204 | 0.110 |
Why?
|
| Genes, Tumor Suppressor | 3 | 2014 | 78 | 0.110 |
Why?
|
| Phenotype | 3 | 2017 | 1242 | 0.110 |
Why?
|
| Temperature | 1 | 2016 | 316 | 0.110 |
Why?
|
| Perches | 1 | 2014 | 2 | 0.110 |
Why?
|
| Oxidative Phosphorylation | 2 | 2012 | 42 | 0.110 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2015 | 88 | 0.110 |
Why?
|
| Parvalbumins | 1 | 2014 | 10 | 0.110 |
Why?
|
| Genome, Mitochondrial | 1 | 2014 | 13 | 0.110 |
Why?
|
| Metal Nanoparticles | 1 | 2017 | 190 | 0.110 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2014 | 15 | 0.110 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2017 | 624 | 0.110 |
Why?
|
| Energy Metabolism | 1 | 2017 | 395 | 0.110 |
Why?
|
| Organ Culture Techniques | 2 | 2005 | 70 | 0.100 |
Why?
|
| Pinctada | 1 | 2013 | 1 | 0.100 |
Why?
|
| Immunoglobulin E | 1 | 2014 | 84 | 0.100 |
Why?
|
| Leukocytes | 1 | 2014 | 104 | 0.100 |
Why?
|
| Biomarkers | 1 | 2019 | 1471 | 0.100 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2013 | 136 | 0.100 |
Why?
|
| Male | 11 | 2023 | 31073 | 0.090 |
Why?
|
| Genotype | 2 | 2020 | 679 | 0.090 |
Why?
|
| DNA Methylation | 1 | 2014 | 305 | 0.090 |
Why?
|
| Aging | 2 | 2012 | 767 | 0.090 |
Why?
|
| Evolution, Molecular | 3 | 2020 | 350 | 0.090 |
Why?
|
| Phylogeny | 3 | 2020 | 395 | 0.090 |
Why?
|
| 9,10-Dimethyl-1,2-benzanthracene | 2 | 2022 | 8 | 0.090 |
Why?
|
| Time Factors | 6 | 2019 | 3789 | 0.090 |
Why?
|
| Carcinogens | 2 | 2022 | 37 | 0.090 |
Why?
|
| Electron Transport Complex I | 1 | 2011 | 15 | 0.090 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2011 | 26 | 0.090 |
Why?
|
| Aged | 5 | 2020 | 14946 | 0.080 |
Why?
|
| Gamma Rays | 3 | 2011 | 32 | 0.080 |
Why?
|
| Calcium-Binding Proteins | 2 | 2010 | 94 | 0.080 |
Why?
|
| Dipeptides | 1 | 2011 | 68 | 0.080 |
Why?
|
| Stem Cell Transplantation | 1 | 2011 | 80 | 0.080 |
Why?
|
| Amyloid Precursor Protein Secretases | 1 | 2011 | 77 | 0.080 |
Why?
|
| Mitogen-Activated Protein Kinase 9 | 1 | 2010 | 46 | 0.080 |
Why?
|
| Prostatic Neoplasms | 1 | 2015 | 495 | 0.080 |
Why?
|
| Oxygen Consumption | 1 | 2011 | 213 | 0.080 |
Why?
|
| Maternal Exposure | 2 | 2021 | 43 | 0.080 |
Why?
|
| Keratins | 1 | 2010 | 32 | 0.080 |
Why?
|
| Mitogen-Activated Protein Kinase 8 | 1 | 2010 | 86 | 0.080 |
Why?
|
| Tumor Microenvironment | 1 | 2011 | 171 | 0.080 |
Why?
|
| Immunohistochemistry | 3 | 2009 | 906 | 0.080 |
Why?
|
| Incidence | 3 | 2012 | 1410 | 0.080 |
Why?
|
| Species Specificity | 2 | 2020 | 348 | 0.080 |
Why?
|
| Endocrine Disruptors | 2 | 2021 | 78 | 0.080 |
Why?
|
| Gene Products, tat | 1 | 2009 | 14 | 0.080 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2010 | 213 | 0.080 |
Why?
|
| Fluorescence | 1 | 2010 | 93 | 0.080 |
Why?
|
| Receptors, Progesterone | 1 | 2010 | 110 | 0.080 |
Why?
|
| Neoplasm Metastasis | 1 | 2009 | 221 | 0.070 |
Why?
|
| Early Growth Response Protein 1 | 1 | 2008 | 17 | 0.070 |
Why?
|
| 14-3-3 Proteins | 1 | 2008 | 20 | 0.070 |
Why?
|
| Placebos | 1 | 2008 | 72 | 0.070 |
Why?
|
| Cell Line, Transformed | 1 | 2008 | 100 | 0.070 |
Why?
|
| Crosses, Genetic | 2 | 2007 | 118 | 0.070 |
Why?
|
| Ovariectomy | 1 | 2008 | 104 | 0.070 |
Why?
|
| Chromatin Assembly and Disassembly | 1 | 2010 | 236 | 0.070 |
Why?
|
| Receptors, Cell Surface | 1 | 2010 | 431 | 0.070 |
Why?
|
| Peptide Fragments | 1 | 2009 | 421 | 0.070 |
Why?
|
| Gene Transfer Techniques | 1 | 2009 | 325 | 0.060 |
Why?
|
| RNA, Small Interfering | 1 | 2013 | 969 | 0.060 |
Why?
|
| Intestine, Small | 1 | 2007 | 81 | 0.060 |
Why?
|
| Epigenesis, Genetic | 1 | 2010 | 407 | 0.060 |
Why?
|
| NF-kappa B | 1 | 2008 | 475 | 0.060 |
Why?
|
| Body Size | 1 | 2026 | 24 | 0.060 |
Why?
|
| Trastuzumab | 1 | 2025 | 20 | 0.060 |
Why?
|
| Fishes | 1 | 2026 | 22 | 0.060 |
Why?
|
| Larva | 1 | 2026 | 158 | 0.060 |
Why?
|
| Blotting, Northern | 1 | 2005 | 152 | 0.060 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2025 | 209 | 0.060 |
Why?
|
| Cloning, Organism | 2 | 2001 | 6 | 0.060 |
Why?
|
| Survival Analysis | 2 | 2010 | 591 | 0.060 |
Why?
|
| Survival Rate | 1 | 2007 | 862 | 0.060 |
Why?
|
| Gene Expression | 2 | 2022 | 864 | 0.050 |
Why?
|
| Karyotyping | 1 | 2004 | 48 | 0.050 |
Why?
|
| Blotting, Southern | 1 | 2004 | 56 | 0.050 |
Why?
|
| Shellfish | 1 | 2024 | 1 | 0.050 |
Why?
|
| Shellfish Hypersensitivity | 1 | 2024 | 4 | 0.050 |
Why?
|
| Blotting, Western | 1 | 2005 | 621 | 0.050 |
Why?
|
| Cell Division | 2 | 2002 | 457 | 0.050 |
Why?
|
| Mutation | 2 | 2011 | 2679 | 0.050 |
Why?
|
| HEPES | 1 | 2023 | 2 | 0.050 |
Why?
|
| Inbreeding | 1 | 2003 | 5 | 0.050 |
Why?
|
| DNA-Activated Protein Kinase | 1 | 2003 | 12 | 0.050 |
Why?
|
| Muscle, Skeletal | 2 | 2020 | 760 | 0.050 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2003 | 53 | 0.050 |
Why?
|
| Nanoparticles | 1 | 2009 | 534 | 0.050 |
Why?
|
| Sperm Motility | 1 | 2023 | 50 | 0.050 |
Why?
|
| Polyethyleneimine | 1 | 2023 | 10 | 0.050 |
Why?
|
| Models, Biological | 1 | 2008 | 1217 | 0.050 |
Why?
|
| Chromosomes | 1 | 2004 | 141 | 0.050 |
Why?
|
| Semen | 1 | 2023 | 50 | 0.050 |
Why?
|
| Molecular Structure | 2 | 2017 | 395 | 0.050 |
Why?
|
| Genetic Vectors | 1 | 2009 | 916 | 0.050 |
Why?
|
| Catalysis | 1 | 2023 | 164 | 0.050 |
Why?
|
| Cytochrome P-450 CYP1A1 | 1 | 2022 | 13 | 0.050 |
Why?
|
| Cell Cycle | 2 | 2001 | 403 | 0.050 |
Why?
|
| Polymorphism, Genetic | 1 | 2003 | 197 | 0.050 |
Why?
|
| Rodentia | 1 | 2022 | 22 | 0.050 |
Why?
|
| Breast Density | 1 | 2022 | 17 | 0.050 |
Why?
|
| Chemoprevention | 1 | 2002 | 41 | 0.050 |
Why?
|
| Animals, Newborn | 1 | 2002 | 245 | 0.040 |
Why?
|
| Environment | 1 | 2022 | 126 | 0.040 |
Why?
|
| Polyethylene Glycols | 1 | 2023 | 174 | 0.040 |
Why?
|
| Nuclear Transfer Techniques | 1 | 2001 | 10 | 0.040 |
Why?
|
| Genes, BRCA1 | 1 | 2000 | 17 | 0.040 |
Why?
|
| Spermatozoa | 1 | 2023 | 265 | 0.040 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2022 | 630 | 0.040 |
Why?
|
| Cross Reactions | 1 | 2020 | 137 | 0.040 |
Why?
|
| Mice, Inbred Strains | 1 | 2000 | 192 | 0.040 |
Why?
|
| Gonadotropins, Equine | 1 | 2000 | 3 | 0.040 |
Why?
|
| Tissue Culture Techniques | 1 | 2020 | 35 | 0.040 |
Why?
|
| Chorionic Gonadotropin | 1 | 2000 | 15 | 0.040 |
Why?
|
| Embryo, Mammalian | 1 | 2001 | 159 | 0.040 |
Why?
|
| Cell Membrane | 1 | 2023 | 510 | 0.040 |
Why?
|
| Calcium Channels, L-Type | 1 | 2020 | 26 | 0.040 |
Why?
|
| Ryanodine Receptor Calcium Release Channel | 1 | 2020 | 45 | 0.040 |
Why?
|
| Cell Polarity | 1 | 2020 | 111 | 0.040 |
Why?
|
| Pituitary Gland | 1 | 2000 | 51 | 0.040 |
Why?
|
| Diagnostic Imaging | 1 | 2023 | 271 | 0.040 |
Why?
|
| Genitalia, Male | 1 | 2019 | 11 | 0.040 |
Why?
|
| Genitalia, Female | 1 | 2019 | 17 | 0.040 |
Why?
|
| Aneuploidy | 1 | 2000 | 42 | 0.040 |
Why?
|
| Cell Line | 3 | 2011 | 2071 | 0.040 |
Why?
|
| Maternal-Fetal Exchange | 1 | 2019 | 32 | 0.040 |
Why?
|
| Muscle Fibers, Skeletal | 1 | 2020 | 95 | 0.040 |
Why?
|
| Gene Deletion | 1 | 2000 | 316 | 0.040 |
Why?
|
| Estrogen Receptor alpha | 1 | 2019 | 50 | 0.040 |
Why?
|
| Genetic Code | 1 | 1999 | 6 | 0.040 |
Why?
|
| Drug Delivery Systems | 1 | 2023 | 332 | 0.040 |
Why?
|
| Molecular Sequence Data | 2 | 2014 | 2017 | 0.040 |
Why?
|
| Puberty | 1 | 2019 | 59 | 0.040 |
Why?
|
| Anal Canal | 1 | 2019 | 38 | 0.040 |
Why?
|
| Cytosol | 1 | 2020 | 183 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 1999 | 33 | 0.040 |
Why?
|
| Biological Evolution | 1 | 2020 | 131 | 0.040 |
Why?
|
| Matrix Metalloproteinase 3 | 1 | 1998 | 6 | 0.040 |
Why?
|
| Weaning | 1 | 1998 | 8 | 0.040 |
Why?
|
| Case-Control Studies | 2 | 2014 | 1157 | 0.040 |
Why?
|
| Muscle Contraction | 1 | 2020 | 202 | 0.040 |
Why?
|
| Calcium Signaling | 1 | 2020 | 165 | 0.040 |
Why?
|
| In Situ Hybridization | 1 | 1998 | 216 | 0.040 |
Why?
|
| Alternative Splicing | 1 | 1999 | 138 | 0.030 |
Why?
|
| Research | 1 | 2019 | 199 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 1999 | 552 | 0.030 |
Why?
|
| Breeding | 1 | 2017 | 29 | 0.030 |
Why?
|
| Genetic Heterogeneity | 1 | 2017 | 21 | 0.030 |
Why?
|
| Gene Ontology | 1 | 2017 | 38 | 0.030 |
Why?
|
| Pyruvic Acid | 1 | 2017 | 14 | 0.030 |
Why?
|
| Macrocyclic Compounds | 1 | 2017 | 12 | 0.030 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2017 | 16 | 0.030 |
Why?
|
| Cell Respiration | 1 | 2017 | 21 | 0.030 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2017 | 28 | 0.030 |
Why?
|
| Molecular Sequence Annotation | 1 | 2017 | 67 | 0.030 |
Why?
|
| Hindlimb | 1 | 2017 | 54 | 0.030 |
Why?
|
| Metabolomics | 1 | 2017 | 60 | 0.030 |
Why?
|
| Regional Blood Flow | 1 | 2017 | 116 | 0.030 |
Why?
|
| Calcium | 1 | 2020 | 589 | 0.030 |
Why?
|
| Cell Differentiation | 1 | 2002 | 1398 | 0.030 |
Why?
|
| Menopause | 1 | 2019 | 261 | 0.030 |
Why?
|
| Neovascularization, Physiologic | 1 | 2017 | 110 | 0.030 |
Why?
|
| Oxidation-Reduction | 1 | 2017 | 331 | 0.030 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2017 | 206 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2017 | 528 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2016 | 169 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2017 | 315 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2017 | 231 | 0.030 |
Why?
|
| Computational Biology | 1 | 2017 | 364 | 0.030 |
Why?
|
| Gold | 1 | 2017 | 235 | 0.030 |
Why?
|
| Sensitivity and Specificity | 2 | 2010 | 1173 | 0.030 |
Why?
|
| Genes, Mitochondrial | 1 | 2014 | 5 | 0.030 |
Why?
|
| Macrophages | 1 | 2020 | 1059 | 0.030 |
Why?
|
| Binding Sites | 1 | 2017 | 930 | 0.030 |
Why?
|
| Sex Factors | 1 | 2017 | 996 | 0.030 |
Why?
|
| Long Interspersed Nucleotide Elements | 1 | 2014 | 18 | 0.030 |
Why?
|
| DNA, Neoplasm | 1 | 2014 | 63 | 0.030 |
Why?
|
| Gene Silencing | 1 | 2017 | 421 | 0.030 |
Why?
|
| Synteny | 1 | 2013 | 24 | 0.030 |
Why?
|
| Expressed Sequence Tags | 1 | 2013 | 28 | 0.030 |
Why?
|
| Microsatellite Repeats | 1 | 2013 | 42 | 0.030 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2014 | 369 | 0.030 |
Why?
|
| Sequence Alignment | 1 | 2014 | 306 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2014 | 265 | 0.030 |
Why?
|
| Carcinogens, Environmental | 1 | 2012 | 6 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2014 | 424 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 1998 | 1580 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2014 | 764 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2017 | 632 | 0.020 |
Why?
|
| Whole-Body Irradiation | 1 | 2011 | 33 | 0.020 |
Why?
|
| G1 Phase | 2 | 2001 | 59 | 0.020 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2011 | 53 | 0.020 |
Why?
|
| Radiation Chimera | 1 | 2011 | 58 | 0.020 |
Why?
|
| Protein Conformation | 1 | 2014 | 792 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2011 | 76 | 0.020 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2011 | 61 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2014 | 1619 | 0.020 |
Why?
|
| Reaction Time | 1 | 2011 | 128 | 0.020 |
Why?
|
| Cattle | 2 | 2001 | 321 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2014 | 1174 | 0.020 |
Why?
|
| Discriminant Analysis | 1 | 2010 | 20 | 0.020 |
Why?
|
| Breast Neoplasms, Male | 1 | 2010 | 14 | 0.020 |
Why?
|
| Cysteine-Rich Protein 61 | 1 | 2009 | 5 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2017 | 726 | 0.020 |
Why?
|
| Protein Binding | 1 | 2014 | 1650 | 0.020 |
Why?
|
| Cyclooxygenase 2 | 1 | 2009 | 78 | 0.020 |
Why?
|
| Neovascularization, Pathologic | 1 | 2009 | 142 | 0.020 |
Why?
|
| Base Sequence | 1 | 2011 | 1346 | 0.020 |
Why?
|
| HeLa Cells | 1 | 2010 | 550 | 0.020 |
Why?
|
| Wound Healing | 1 | 2009 | 196 | 0.020 |
Why?
|
| Age Factors | 1 | 2012 | 1593 | 0.020 |
Why?
|
| Genome, Human | 1 | 2009 | 242 | 0.020 |
Why?
|
| Transfection | 1 | 2009 | 707 | 0.020 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 2007 | 42 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2010 | 697 | 0.020 |
Why?
|
| Fenretinide | 1 | 2005 | 3 | 0.010 |
Why?
|
| Retinoid X Receptors | 1 | 2005 | 15 | 0.010 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2005 | 49 | 0.010 |
Why?
|
| Tretinoin | 1 | 2005 | 51 | 0.010 |
Why?
|
| Ovary | 1 | 2005 | 106 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2009 | 1701 | 0.010 |
Why?
|
| Child | 1 | 2014 | 4678 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2005 | 379 | 0.010 |
Why?
|
| Cell Death | 1 | 2005 | 290 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2005 | 882 | 0.010 |
Why?
|
| Culture Media, Serum-Free | 1 | 2001 | 10 | 0.010 |
Why?
|
| Resting Phase, Cell Cycle | 1 | 2001 | 11 | 0.010 |
Why?
|
| Antimetabolites | 1 | 2001 | 18 | 0.010 |
Why?
|
| Bromodeoxyuridine | 1 | 2001 | 44 | 0.010 |
Why?
|
| Culture Techniques | 1 | 2001 | 12 | 0.010 |
Why?
|
| Cell Count | 1 | 2001 | 133 | 0.010 |
Why?
|
| S Phase | 1 | 2001 | 80 | 0.010 |
Why?
|
| Cell Survival | 1 | 2001 | 601 | 0.010 |
Why?
|